Want to see IN:ASTEC full AI Analyst Report?
ASTEC Stock Chart & Stats
₹703.50
-₹43.60(-3.76%)
At close: 4:00 PM EST
₹703.50
-₹43.60(-3.76%)
Day’s Range― - ―
52-Week Range₹512.35 - ₹936.00
Previous CloseN/A
Volume22.45K
Average Volume (3M)19.22K
Market Cap
₹16.07B
Enterprise Value₹16.39B
Total Cash (Recent Filing)₹100.49M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Oct 23, 2026EPS Estimate
-15.9Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)-30.27
Shares Outstanding22,282,820
10 Day Avg. Volume3,525
30 Day Avg. Volume19,217
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)2.96
Price to Sales (P/S)2.58
P/FCF Ratio-9.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.73
Revenue Forecast (FY)₹5.26B
Bulls Say, Bears Say
Bulls Say
FY26 Revenue RecoveryThe 18.5% FY26 revenue rebound indicates that top-line demand recovered after two difficult years. If maintained, stronger volumes or pricing could improve fixed-cost absorption and create a foundation for restoring profitability, although margins remain weak.
Broad Crop-Protection PortfolioAstec participates across insecticide, herbicide, and fungicide applications rather than relying on one crop-protection category. This breadth can support relevance with formulators and agricultural-input customers across different end markets over the medium term.
Substantial Equity And Asset BaseA substantial equity and asset base provides some underlying financial capacity while Astec works through losses and elevated leverage. This does not remove balance-sheet pressure, but it is a constructive foundation for supporting operations and potential recovery efforts.
Bears Say
Sustained Large LossesThe shift from positive earnings to sizable losses across FY24–FY26 indicates that the recent revenue rebound has not translated into viable profitability. Persistent negative operating profit can constrain reinvestment, weaken resilience, and make recovery dependent on a material earnings improvement.
Higher LeverageThe sharp increase in debt relative to equity reduces financial flexibility as the company faces continued losses. Elevated leverage can increase pressure on future cash flows and limit the ability to fund operations or growth without further balance-sheet support.
Negative Cash GenerationRecent operating cash burn and recurring free-cash-flow deficits show that the business has not been self-funding. Continued negative cash generation may require financing or balance-sheet support, increasing execution risk and limiting durable capital-allocation flexibility.
Astec Lifesciences Limited News
ASTEC FAQ
What was Astec Lifesciences Limited’s price range in the past 12 months?
Astec Lifesciences Limited lowest stock price was ₹512.35 and its highest was ₹936.00 in the past 12 months.
What is Astec Lifesciences Limited’s market cap?
Astec Lifesciences Limited’s market cap is ₹16.07B.
When is Astec Lifesciences Limited’s upcoming earnings report date?
Astec Lifesciences Limited’s upcoming earnings report date is Oct 23, 2026 which is in 6 days.
How were Astec Lifesciences Limited’s earnings last quarter?
Astec Lifesciences Limited released its earnings results on Jul 31, 2026. The company reported -₹8.4 earnings per share for the quarter, beating the consensus estimate of -₹8.85 by ₹0.45.
Is Astec Lifesciences Limited overvalued?
According to Wall Street analysts Astec Lifesciences Limited’s price is currently Overvalued.
Does Astec Lifesciences Limited pay dividends?
Astec Lifesciences Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 0.12%. See more information on Astec Lifesciences Limited dividends here
What is Astec Lifesciences Limited’s EPS estimate?
Astec Lifesciences Limited’s EPS estimate is -15.9.
How many shares outstanding does Astec Lifesciences Limited have?
Astec Lifesciences Limited has 22,282,820 shares outstanding.
What happened to Astec Lifesciences Limited’s price movement after its last earnings report?
Astec Lifesciences Limited reported an EPS of -₹8.4 in its last earnings report, beating expectations of -₹8.85. Following the earnings report the stock price went up 4.643%.
Which hedge fund is a major shareholder of Astec Lifesciences Limited?
Currently, no hedge funds are holding shares in IN:ASTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astec Lifesciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservative. It also provides herbicides, insecticides, and specialty chemical products. The company also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.
Technical Analysis
Bharat Rasayan Limited
―
Dhanuka Agritech Limited
―
Insecticides (India) Limited
―
India Pesticides Ltd.
―
Sharda Cropchem Ltd.
―